Mainz Biomed Commits to Innovative Research Collaboration with Fugene Genetics in Israel

Mainz Biomed NV (NASDAQ: MYNZ) is proud to announce a commercial partnership with Fugene Genetics, an esteemed provider of genetic testing services in Israel. Established in 2008, Fugene Genetics offers a comprehensive range of cutting-edge genetic testing services to medical professionals, hospitals, health organizations and private customers.

Through this partnership, MainzBiomed aims to further increase the accessibility of its ColoAlert diagnostic test, which specializes in the early detection of cancer.

Mainz Biomed is revolutionizing the screening of colorectal cancer with their flagship product, ColoAlert – a user-friendly and cost-effective at-home test. They have chosen a unique business model of partnering with third-party labs and experienced distribution companies to provide test kits, allowing them to expand globally in Europe and select international markets. Taking this approach, they are going beyond the traditional single facility model and are raising the bar on CRC detection.

Mainz Biomed is thrilled to announce that they have partnered with experienced international partner Fugene Genetics to provide better market access for their ColoAlert product globally. Fugene Genetics, with a record of success introducing novel molecular diagnostic products in the Israeli market, are well-equipped with a large commercial network and relationships with prominent laboratories. This partnership is sure to meet the urgent need for useful products with improved clinical results.

Mainz Biomed and Fugene Genetics are excited to announce the launch of ColoAlert in Israel – a revolutionary cancer screening solution. With over one million people screened each year, Israel has one of the highest compliance rates in the world.

It is expected that over 3.5 million adults will benefit from the availability of ColoAlert. The two companies are actively collaborating to launch an effective and successful commercial campaign that will provide the highest quality of cancer screening care to people across the nation.

We are delighted to join forces with Mainz Biomed to launch ColoAlert, an innovative early screening test for colon cancer, and make it available to our clients in Israel. Fugene Genetics is committed to introducing cutting-edge genetic testing solutions and improving health outcomes, and this partnership is an ideal way to do just that.

ColoAlert’s effectiveness and user-friendliness give it great potential to enable early detection of colon cancer and make a meaningful impact. With our well-established network of healthcare providers and strong relationships with them, we are confident that we will be able to promote ColoAlert and make the most of this commercial partnership.

About ColoAlert®

ColoAlert from Mainz Biomed is transforming the early detection of colorectal cancer (CRC) with its non-invasive and high accuracy stool test. Utilizing PCR-technology, this product has been proven to have superior performance compared to traditional fecal occult blood tests (FOBT).

Currently, ColoAlert is available in select EU countries through independent laboratories, corporate health programs, and direct sales and is undergoing FDA evaluation in the US in the ‘ReconAAsense’ clinical trial. Once approved, Mainz Biomed plans to roll out this innovative product through a scalable distribution network with laboratory service providers across the nation.

About Colorectal Cancer

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers in the world – with over 1.9 million cases being reported in 2020 according to the World Cancer Research Fund International – making it the third most common cancer globally. To prevent its spread, the US Preventive Services Task Force recommends stool DNA tests such as ColoAlert be conducted every three years starting at age 45.

Despite this recommendation, nearly one-third of US residents aged 50-75 have never been screened for colon cancer – representing an untapped market worth an estimated $4.0 billion in the US alone. Evidently, there is a high potential to increase cancer prevention awareness and patient adherence in this population.

About Mainz Biomed NV

Mainz Biomed NV is revolutionizing the way early-stage cancer is detected. Its flagship product, ColoAlert, offers a cutting-edge, non-invasive diagnostic test for colorectal cancer based on the Polymerase Chain Reaction (PCR) technology.

Already available in Europe, the company is undergoing a pivotal FDA clinical study for US approval and also has PancAlert, an early-stage pancreatic cancer screening test in the pipeline. With its suite of molecular genetic diagnostic solutions, Mainz Biomed is transforming the life-threatening conditions diagnostics landscape.

Leave a Comment